In connection with the chapter 11 filing, on November 30, 2018, the Argos Therapeutics, Inc. terminated the employment of Jeffrey D. Abbey, President and Chief Executive Officer of the company, Richard D. Katz, Chief Financial Officer of the company and Charles Nicolette, Chief Scientific Officer and Vice President of Research and Development of the Company. Each of Mr. Abbey and Drs. Katz and Nicolette will remain available as consultants to the company pursuant to consulting agreements previously entered into on August 29, 2018, which consulting agreements were previously filed as exhibits to the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 19, 2018.

Mr. Abbey will also continue to serve as a director of the company. In addition, on November 29, 2018 and following approval of the chapter 11 filing and related actions, Hubert Birner, Robert F. Carey and Irackly Mtibelishvily resigned from the Board of Directors of the company, effective as of the filing of the Voluntary Petition with the Court. At the time of resignation, Dr. Birner was a member of the Audit Committee and Nominating and Corporate Governance Committee of the Board, Mr. Carey was a member of the Audit Committee and the Compensation Committee of the Board and Mr. Mtibelishvily was a member of the Nominating and Corporate Governance Committee of the Board.

The resignations are not the result of any disagreement with the Company regarding the Company's operations, policies or practices.